Mammalian  ||| S:0 E:10 ||| JJ
target  ||| S:10 E:17 ||| NN
of  ||| S:17 E:20 ||| IN
rapamycin ||| S:20 E:29 ||| NNS
:  ||| S:29 E:31 ||| :
discovery  ||| S:31 E:41 ||| NN
of  ||| S:41 E:44 ||| IN
rapamycin  ||| S:44 E:54 ||| NN
reveals  ||| S:54 E:62 ||| VBZ
a  ||| S:62 E:64 ||| DT
signaling  ||| S:64 E:74 ||| JJ
pathway  ||| S:74 E:82 ||| JJ
important  ||| S:82 E:92 ||| JJ
for  ||| S:92 E:96 ||| IN
normal  ||| S:96 E:103 ||| JJ
and  ||| S:103 E:107 ||| CC
cancer  ||| S:107 E:114 ||| NN
cell  ||| S:114 E:119 ||| NN
growth  ||| S:119 E:126 ||| NN
Since  ||| S:126 E:132 ||| IN
the  ||| S:132 E:136 ||| DT
discovery  ||| S:136 E:146 ||| NN
of  ||| S:146 E:149 ||| IN
rapamycin ||| S:149 E:158 ||| NN
,  ||| S:158 E:160 ||| ,
considerable  ||| S:160 E:173 ||| JJ
progress  ||| S:173 E:182 ||| NN
has  ||| S:182 E:186 ||| VBZ
been  ||| S:186 E:191 ||| VBN
made  ||| S:191 E:196 ||| VBN
in  ||| S:196 E:199 ||| IN
unraveling  ||| S:199 E:210 ||| VBG
the  ||| S:210 E:214 ||| DT
details  ||| S:214 E:222 ||| NNS
of  ||| S:222 E:225 ||| IN
the  ||| S:225 E:229 ||| DT
mammalian  ||| S:229 E:239 ||| JJ
target  ||| S:239 E:246 ||| NN
of  ||| S:246 E:249 ||| IN
rapamycin  ||| S:249 E:259 ||| NNS
( ||| S:259 E:260 ||| -LRB-
mTOR ||| S:260 E:264 ||| NNP
)  ||| S:264 E:266 ||| -RRB-
signaling  ||| S:266 E:276 ||| VBG
network ||| S:276 E:283 ||| NN
,  ||| S:283 E:285 ||| ,
including  ||| S:285 E:295 ||| VBG
the  ||| S:295 E:299 ||| DT
upstream  ||| S:299 E:308 ||| JJ
mechanisms  ||| S:308 E:319 ||| NNS
that  ||| S:319 E:324 ||| WDT
modulate  ||| S:324 E:333 ||| VBP
mTOR  ||| S:333 E:338 ||| JJ
signaling  ||| S:338 E:348 ||| JJ
functions ||| S:348 E:357 ||| NNS
,  ||| S:357 E:359 ||| ,
and  ||| S:359 E:363 ||| CC
the  ||| S:363 E:367 ||| DT
roles  ||| S:367 E:373 ||| NNS
of  ||| S:373 E:376 ||| IN
mTOR  ||| S:376 E:381 ||| JJ
in  ||| S:381 E:384 ||| IN
the  ||| S:384 E:388 ||| DT
regulation  ||| S:388 E:399 ||| NN
of  ||| S:399 E:402 ||| IN
mRNA  ||| S:402 E:407 ||| JJ
translation  ||| S:407 E:419 ||| NN
and  ||| S:419 E:423 ||| CC
other  ||| S:423 E:429 ||| JJ
cell  ||| S:429 E:434 ||| NN
growth-related  ||| S:434 E:449 ||| NNP
responses.  ||| S:449 E:460 ||| NNP
mTOR  ||| S:460 E:465 ||| NNP
is  ||| S:465 E:468 ||| VBZ
found  ||| S:468 E:474 ||| VBN
in  ||| S:474 E:477 ||| IN
two  ||| S:477 E:481 ||| CD
different  ||| S:481 E:491 ||| JJ
complexes  ||| S:491 E:501 ||| NNS
within  ||| S:501 E:508 ||| IN
the  ||| S:508 E:512 ||| DT
cell ||| S:512 E:516 ||| NN
,  ||| S:516 E:518 ||| ,
mTORC1  ||| S:518 E:525 ||| NNP
and  ||| S:525 E:529 ||| CC
mTORC2 ||| S:529 E:535 ||| NNP
,  ||| S:535 E:537 ||| ,
but  ||| S:537 E:541 ||| CC
only  ||| S:541 E:546 ||| JJ
mTORC1  ||| S:546 E:553 ||| NN
is  ||| S:553 E:556 ||| VBZ
sensitive  ||| S:556 E:566 ||| JJ
to  ||| S:566 E:569 ||| TO
inhibition  ||| S:569 E:580 ||| VB
by  ||| S:580 E:583 ||| IN
rapamycin.  ||| S:583 E:594 ||| NNP
mTORC1  ||| S:594 E:601 ||| NNP
is  ||| S:601 E:604 ||| VBZ
a  ||| S:604 E:606 ||| DT
master  ||| S:606 E:613 ||| NN
controller  ||| S:613 E:624 ||| NN
of  ||| S:624 E:627 ||| IN
protein  ||| S:627 E:635 ||| NN
synthesis ||| S:635 E:644 ||| NN
,  ||| S:644 E:646 ||| ,
integrating  ||| S:646 E:658 ||| VBG
signals  ||| S:658 E:666 ||| NNS
from  ||| S:666 E:671 ||| IN
growth  ||| S:671 E:678 ||| NN
factors  ||| S:678 E:686 ||| NNS
within  ||| S:686 E:693 ||| IN
the  ||| S:693 E:697 ||| DT
context  ||| S:697 E:705 ||| NN
of  ||| S:705 E:708 ||| IN
the  ||| S:708 E:712 ||| DT
energy  ||| S:712 E:719 ||| NN
and  ||| S:719 E:723 ||| CC
nutritional  ||| S:723 E:735 ||| JJ
conditions  ||| S:735 E:746 ||| NNS
of  ||| S:746 E:749 ||| IN
the  ||| S:749 E:753 ||| DT
cell ||| S:753 E:757 ||| NN
.  ||| S:757 E:759 ||| .
Activated  ||| S:759 E:769 ||| NNP
mTORC1  ||| S:769 E:776 ||| NNP
regulates  ||| S:776 E:786 ||| VBZ
protein  ||| S:786 E:794 ||| JJ
synthesis  ||| S:794 E:804 ||| NN
by  ||| S:804 E:807 ||| IN
directly  ||| S:807 E:816 ||| RB
phosphorylating  ||| S:816 E:832 ||| CD
4E-binding  ||| S:832 E:843 ||| CD
protein  ||| S:843 E:851 ||| CD
1  ||| S:851 E:853 ||| CD
( ||| S:853 E:854 ||| -LRB-
4E-BP1 ||| S:854 E:860 ||| NNP
)  ||| S:860 E:862 ||| -RRB-
and  ||| S:862 E:866 ||| CC
p70S6K  ||| S:866 E:873 ||| NNP
( ||| S:873 E:874 ||| -LRB-
S6K ||| S:874 E:877 ||| NNP
) ||| S:877 E:878 ||| -RRB-
,  ||| S:878 E:880 ||| ,
translation  ||| S:880 E:892 ||| JJ
initiation  ||| S:892 E:903 ||| NN
factors  ||| S:903 E:911 ||| NNS
that  ||| S:911 E:916 ||| WDT
are  ||| S:916 E:920 ||| VBP
important  ||| S:920 E:930 ||| JJ
to  ||| S:930 E:933 ||| TO
cap-dependent  ||| S:933 E:947 ||| JJ
mRNA  ||| S:947 E:952 ||| JJ
translation ||| S:952 E:963 ||| NN
,  ||| S:963 E:965 ||| ,
which  ||| S:965 E:971 ||| WDT
increases  ||| S:971 E:981 ||| VBZ
the  ||| S:981 E:985 ||| DT
level  ||| S:985 E:991 ||| NN
of  ||| S:991 E:994 ||| IN
many  ||| S:994 E:999 ||| JJ
proteins  ||| S:999 E:1008 ||| NNS
that  ||| S:1008 E:1013 ||| WDT
are  ||| S:1013 E:1017 ||| VBP
needed  ||| S:1017 E:1024 ||| VBN
for  ||| S:1024 E:1028 ||| IN
cell  ||| S:1028 E:1033 ||| NN
cycle  ||| S:1033 E:1039 ||| NN
progression ||| S:1039 E:1050 ||| NN
,  ||| S:1050 E:1052 ||| ,
proliferation ||| S:1052 E:1065 ||| NN
,  ||| S:1065 E:1067 ||| ,
angiogenesis ||| S:1067 E:1079 ||| NN
,  ||| S:1079 E:1081 ||| ,
and  ||| S:1081 E:1085 ||| CC
survival  ||| S:1085 E:1094 ||| NN
pathways ||| S:1094 E:1102 ||| NN
.  ||| S:1102 E:1104 ||| .
In  ||| S:1104 E:1107 ||| IN
normal  ||| S:1107 E:1114 ||| JJ
physiology ||| S:1114 E:1124 ||| NN
,  ||| S:1124 E:1126 ||| ,
the  ||| S:1126 E:1130 ||| DT
roles  ||| S:1130 E:1136 ||| NNS
of  ||| S:1136 E:1139 ||| IN
mTOR  ||| S:1139 E:1144 ||| JJ
in  ||| S:1144 E:1147 ||| IN
both  ||| S:1147 E:1152 ||| DT
glucose  ||| S:1152 E:1160 ||| NN
and  ||| S:1160 E:1164 ||| CC
lipid  ||| S:1164 E:1170 ||| JJ
catabolism  ||| S:1170 E:1181 ||| NNS
underscore  ||| S:1181 E:1192 ||| VBP
the  ||| S:1192 E:1196 ||| DT
importance  ||| S:1196 E:1207 ||| NN
of  ||| S:1207 E:1210 ||| IN
the  ||| S:1210 E:1214 ||| DT
mTOR  ||| S:1214 E:1219 ||| JJ
pathway  ||| S:1219 E:1227 ||| NN
in  ||| S:1227 E:1230 ||| IN
the  ||| S:1230 E:1234 ||| DT
production  ||| S:1234 E:1245 ||| NN
of  ||| S:1245 E:1248 ||| IN
metabolic  ||| S:1248 E:1258 ||| JJ
energy  ||| S:1258 E:1265 ||| NN
in  ||| S:1265 E:1268 ||| IN
quantities  ||| S:1268 E:1279 ||| NNS
sufficient  ||| S:1279 E:1290 ||| JJ
to  ||| S:1290 E:1293 ||| TO
fuel  ||| S:1293 E:1298 ||| VB
cell  ||| S:1298 E:1303 ||| NN
growth  ||| S:1303 E:1310 ||| NN
and  ||| S:1310 E:1314 ||| CC
mitotic  ||| S:1314 E:1322 ||| JJ
cell  ||| S:1322 E:1327 ||| NN
division ||| S:1327 E:1335 ||| NN
.  ||| S:1335 E:1337 ||| .
Several  ||| S:1337 E:1345 ||| JJ
oncogenes  ||| S:1345 E:1355 ||| NNS
and  ||| S:1355 E:1359 ||| CC
tumor-suppressor  ||| S:1359 E:1376 ||| JJ
genes  ||| S:1376 E:1382 ||| NNS
that  ||| S:1382 E:1387 ||| WDT
activate  ||| S:1387 E:1396 ||| VBP
mTORC1 ||| S:1396 E:1402 ||| RB
,  ||| S:1402 E:1404 ||| ,
often  ||| S:1404 E:1410 ||| RB
through  ||| S:1410 E:1418 ||| IN
the  ||| S:1418 E:1422 ||| DT
phosphatidylinositol  ||| S:1422 E:1443 ||| JJ
3-kinase  ||| S:1443 E:1452 ||| NNP
( ||| S:1452 E:1453 ||| -LRB-
PI3K ||| S:1453 E:1457 ||| NNP
) ||| S:1457 E:1458 ||| -RRB-
/ ||| S:1458 E:1459 ||| NNP
AKT  ||| S:1459 E:1463 ||| NNP
pathway ||| S:1463 E:1470 ||| NN
,  ||| S:1470 E:1472 ||| ,
are  ||| S:1472 E:1476 ||| VBP
frequently  ||| S:1476 E:1487 ||| RB
dysregulated  ||| S:1487 E:1500 ||| VBN
in  ||| S:1500 E:1503 ||| IN
cancer ||| S:1503 E:1509 ||| NN
.  ||| S:1509 E:1511 ||| .
Novel  ||| S:1511 E:1517 ||| NN
analogs  ||| S:1517 E:1525 ||| NN
of  ||| S:1525 E:1528 ||| IN
rapamycin  ||| S:1528 E:1538 ||| NNS
( ||| S:1538 E:1539 ||| -LRB-
temsirolimus ||| S:1539 E:1551 ||| UH
,  ||| S:1551 E:1553 ||| ,
everolimus ||| S:1553 E:1563 ||| NN
,  ||| S:1563 E:1565 ||| ,
and  ||| S:1565 E:1569 ||| CC
deforolimus ||| S:1569 E:1580 ||| CD
) ||| S:1580 E:1581 ||| -RRB-
,  ||| S:1581 E:1583 ||| ,
which  ||| S:1583 E:1589 ||| WDT
have  ||| S:1589 E:1594 ||| VBP
improved  ||| S:1594 E:1603 ||| VBN
pharmaceutical  ||| S:1603 E:1618 ||| JJ
properties ||| S:1618 E:1628 ||| NNS
,  ||| S:1628 E:1630 ||| ,
were  ||| S:1630 E:1635 ||| VBD
designed  ||| S:1635 E:1644 ||| VBN
for  ||| S:1644 E:1648 ||| IN
oncology  ||| S:1648 E:1657 ||| JJ
indications ||| S:1657 E:1668 ||| NNS
.  ||| S:1668 E:1670 ||| .
Clinical  ||| S:1670 E:1679 ||| JJ
trials  ||| S:1679 E:1686 ||| NNS
of  ||| S:1686 E:1689 ||| IN
these  ||| S:1689 E:1695 ||| DT
analogs  ||| S:1695 E:1703 ||| NNS
have  ||| S:1703 E:1708 ||| VBP
already  ||| S:1708 E:1716 ||| RB
validated  ||| S:1716 E:1726 ||| VB
the  ||| S:1726 E:1730 ||| DT
importance  ||| S:1730 E:1741 ||| NN
of  ||| S:1741 E:1744 ||| IN
mTOR  ||| S:1744 E:1749 ||| JJ
inhibition  ||| S:1749 E:1760 ||| NN
as  ||| S:1760 E:1763 ||| IN
a  ||| S:1763 E:1765 ||| DT
novel  ||| S:1765 E:1771 ||| NN
treatment  ||| S:1771 E:1781 ||| NN
strategy  ||| S:1781 E:1790 ||| NN
for  ||| S:1790 E:1794 ||| IN
several  ||| S:1794 E:1802 ||| JJ
malignancies ||| S:1802 E:1814 ||| NN
.  ||| S:1814 E:1816 ||| .
Inhibition  ||| S:1816 E:1827 ||| NNP
of  ||| S:1827 E:1830 ||| IN
mTOR  ||| S:1830 E:1835 ||| JJ
now  ||| S:1835 E:1839 ||| RB
represents  ||| S:1839 E:1850 ||| VBZ
an  ||| S:1850 E:1853 ||| DT
attractive  ||| S:1853 E:1864 ||| JJ
anti-tumor  ||| S:1864 E:1875 ||| JJ
target ||| S:1875 E:1881 ||| NN
,  ||| S:1881 E:1883 ||| ,
either  ||| S:1883 E:1890 ||| CC
alone  ||| S:1890 E:1896 ||| RB
or  ||| S:1896 E:1899 ||| CC
in  ||| S:1899 E:1902 ||| IN
combination  ||| S:1902 E:1914 ||| NN
with  ||| S:1914 E:1919 ||| IN
strategies  ||| S:1919 E:1930 ||| NNS
to  ||| S:1930 E:1933 ||| TO
target  ||| S:1933 E:1940 ||| VB
other  ||| S:1940 E:1946 ||| JJ
pathways  ||| S:1946 E:1955 ||| NN
that  ||| S:1955 E:1960 ||| WDT
may  ||| S:1960 E:1964 ||| MD
overcome  ||| S:1964 E:1973 ||| VB
resistance ||| S:1973 E:1983 ||| NN
.  ||| S:1983 E:1985 ||| .
The  ||| S:1985 E:1989 ||| DT
far-reaching  ||| S:1989 E:2002 ||| JJ
downstream  ||| S:2002 E:2013 ||| JJ
consequences  ||| S:2013 E:2026 ||| NNS
of  ||| S:2026 E:2029 ||| IN
mTOR  ||| S:2029 E:2034 ||| JJ
inhibition  ||| S:2034 E:2045 ||| NNS
make  ||| S:2045 E:2050 ||| VBP
defining  ||| S:2050 E:2059 ||| VBG
the  ||| S:2059 E:2063 ||| DT
critical  ||| S:2063 E:2072 ||| JJ
molecular  ||| S:2072 E:2082 ||| JJ
effector  ||| S:2082 E:2091 ||| JJ
mechanisms  ||| S:2091 E:2102 ||| NNS
that  ||| S:2102 E:2107 ||| WDT
mediate  ||| S:2107 E:2115 ||| VBZ
the  ||| S:2115 E:2119 ||| DT
anti-tumor  ||| S:2119 E:2130 ||| JJ
response  ||| S:2130 E:2139 ||| NN
and  ||| S:2139 E:2143 ||| CC
associated  ||| S:2143 E:2154 ||| JJ
biomarkers  ||| S:2154 E:2165 ||| NN
that  ||| S:2165 E:2170 ||| WDT
predict  ||| S:2170 E:2178 ||| VBP
responsiveness  ||| S:2178 E:2193 ||| VBN
to  ||| S:2193 E:2196 ||| TO
mTOR  ||| S:2196 E:2201 ||| JJ
inhibitors  ||| S:2201 E:2212 ||| NNS
a  ||| S:2212 E:2214 ||| DT
challenge  ||| S:2214 E:2224 ||| NN
and  ||| S:2224 E:2228 ||| CC
priority  ||| S:2228 E:2237 ||| NN
for  ||| S:2237 E:2241 ||| IN
the  ||| S:2241 E:2245 ||| DT
field ||| S:2245 E:2250 ||| NN
.  ||| S:2250 E:2252 ||| .
